Robert C. Penland - Concepedia

Author

Robert C. Penland

Also Known As

D GRAHAM, Penland, Robert C., R Christian Penland, R PENLAND, R. C. Penland, R. Christian Penland, R. Penland, R.C. Penland, R.Christian Penland, ROBERT C. PENLAND

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Duke University AstraZeneca (Sweden)AstraZeneca (Poland)University of Groningen

About

Robert C. Penland is an author at AstraZeneca (United States) specializing in medicine, cardiology, and electrophysiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	142
2	Engineering	4	4	117
3	Biomedical Engineering	3	3	103
4	Anatomy	1	1	13
5	Cell Biology	1	1	14

Robert C. Penland

Publications

939

Citations

H-Index

Page 1

	Year	Citations
Magnetic resonance myocardial fiber-orientation mapping with direct histological correlation Edward W. Hsu, A.L. Muzikant, Susan A. Matulevicius, American Journal of Physiology-Heart and Circulatory Physiology	1998	383
Novel Orally Swallowable IntelliCap® Device to Quantify Regional Drug Absorption in Human GI Tract Using Diltiazem as Model Drug D. E. Becker, Jin Zhang, Tycho Heimbach, AAPS PharmSciTech	2014	99
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, Cardiovascular Diabetology	2019	77
Modeling impulse propagation and extracellular potential distributions in anisotropic cardiac tissue using a finite volume element discretization Robert C. Penland, David M. Harrild, Craig S. Henriquez Computing and Visualization in Science Numerical AnalysisCardiac MuscleEngineeringCardiac MechanicExtracellular Potential Distributions	2002	57
Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation Gül Erdemli, Albert M. Kim, Haisong Ju, Frontiers in Pharmacology	2012	47
Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling Victor Sokolov, Tatiana A. Yakovleva, Lulu Chu, CPT Pharmacometrics & Systems Pharmacology	2020	38
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors Tatiana A. Yakovleva, Victor Sokolov, Lulu Chu, Diabetes Obesity and Metabolism	2019	35
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the <scp>EXSCEL</scp> trial Annemarie B. van der Aart‐van der Beek, Lindsay E. Clegg, Robert C. Penland, Diabetes Obesity and Metabolism	2020	34
A flexible method for simulating cardiac conduction in three-dimensional complex geometries David M. Harrild, Robert C. Penland, Craig S. Henriquez Journal of Electrocardiology Numerical AnalysisCardiac MuscleThree-dimensional Complex GeometriesEngineeringCardiac Mechanic	2000	33
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Diabetes Care	2018	32

Page 1